Create a narrative

Syndax Pharmaceuticals Community

NasdaqGS:SNDX Community

1 Narratives written by author
0 Comments on narratives written by author
5 Fair Values set on narratives written by author

Create a narrative

Syndax Pharmaceuticals

AN

AnalystConsensusTarget

AnalystConsensusTarget

Consensus Narrative from 12 Analysts

FDA Approvals Will Expand AML And cGVHD Treatment Options

Key Takeaways Recent FDA approvals and strategic collaborations position Syndax to significantly enhance revenue and address unmet clinical needs in oncology. Strong financial backing supports operational funding and long-term profitability, enhancing margins and enabling strategic market expansion.

US$32.67

FV

69.6% undervalued

117.82%

Revenue growth p.a.

0

0

3

8 days ago